After GLP-1s Went Mainstream for Humans, Obese Pets Are Next

The weight-loss revolution that transformed human healthcare is now coming for household pets, as Chinese pharma companies race to bring GLP-1 treatments to the booming market of overweight cats and dogs.

According to sources, Irina Zhou’s five-year-old cat has been packing on roughly 2.2 lbs (1 kilogram) annually for three years. While Zhou recognizes the health risks, her family’s affection for their feline makes dietary restriction challenging.

“My parents just can’t bear to see the cat go hungry,” the 29-year-old Zhou said. “If the weight starts to affect his health, I might consider trying weight-loss meds for him.”

Her concerns reflect a growing trend across China, where prosperity has led to increasingly pampered pets facing the same obesity epidemic as their owners. Now pharmaceutical companies are responding with veterinary versions of medications that have already reshaped human weight management.

A unit of Huadong Medicine recently received acceptance notices from Chinese regulators for veterinary d**g registration applications targeting weight management in adult obese cats, indicating the treatment could soon enter the domestic market. Shanghai Fosun Pharmaceutical is also exploring similar territory, according to industry reports.

These animal formulations work through GLP-1 receptor agonists, d**gs designed to mimic a naturally occurring hormone that regulates appetite and metabolism. In humans, brands like Ozempic and Wegovy have become cultural phenomena, generating billions in revenue while sparking debates about necessity versus cosmetic use.

The pet market represents a different calculus entirely. Unlike humans who can articulate their health concerns and make informed decisions, pets depend entirely on owner judgment about when extra pounds cross from endearing to dangerous. Many owners face the same dilemma as Zhou’s parents: balancing the immediate pleasure of a well-fed pet against long-term health consequences including diabetes, joint problems, and reduced lifespan.

China’s pet economy has expanded rapidly alongside the country’s middle class, with owners increasingly willing to invest in premium food, accessories, and medical care. This creates fertile ground for pharmaceutical innovation adapted from human medicine.

The technology behind these treatments centers on extending the activity of GLP-1, a hormone that normally disappears from the bloodstream within minutes. By making it last longer, the d**gs help reduce appetite and improve metabolic function, potentially offering a medical solution where willpower and portion control have proved insufficient.